Paroxetine



























  1. Subgroup evaluations normally did not suggest differences in therapy end results as a feature of gender, age, or race. Generalized Anxiety Disorder.



    The effectiveness of Paroxetine hydrochloride in the treatment of Generalized Anxiety Disorder (GAD) was demonstrated in 2 8-week, multicenter, placebo-controlled research studies (Studies 1 and 2) of adult outpatients regarding Generalized Anxiety Disorder (DSM-IV).



    Research study 1 was an 8-week research comparing taken care of Paroxetine doses of 20 milligrams or 40 mg/day with inactive medicine. Dosages of 20 mg or 40 milligrams of Paroxetine hydrochloride were both demonstrated to be considerably above placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score. There was not adequate proof in this research study to recommend a higher benefit for the 40 mg/day dosage as compared to the 20 mg/day dose.



    Research 2 was a flexible-dose research contrasting Paroxetine (20 milligrams to 50 mg everyday) as well as inactive medicine. Paroxetine hydrochloride showed statistically substantial supremacy over sugar pill on the Hamilton Rating Scale for Anxiety (HAM-A) complete rating. A 3rd research, additionally flexible-dose contrasting Paroxetine (20 milligrams to 50 milligrams daily), did not demonstrate statistically considerable superiority of Paroxetine hydrochloride over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, the main result.